MCK's Quality Score fell 1 point on Mon, Nov 2, to 15.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 391% over five years while the S&P 500 rose 76%.
“Within the segment, sales to U.S. pharmacies and healthcare providers increased $31.6 billion primarily due to higher volumes from retail national account customers”
| The company | 5% fewer shares than a year ago |
| Latest filing | 8-K, Oct 6 |
ReportReports Wednesday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +3.8% on average. Past reports ›
Tue Dec 1: Ex-dividend, $0.94 a shareAt the open. Pays Jan 4.
After its last 4 reports it closed +3.8% on average, higher 2 of 4 times.
Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
MCK is #1 of 5 by Quality Score among Wholesale-Drugs, Proprietaries & Druggists' Sundries.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score |
Share count against a year before: MCK -5%, COR -0.3%, CAH -2.1%.
Reports Wed Nov 4, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“First quarter revenues were $105.4 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes and distribution of specialty products, partially offset by lower contributions from branded pharmaceuticals.”
MCK's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Adjusted earnings per diluted share | $44.20 to $45.00 |
“First quarter Adjusted Earnings per Diluted Share was $9.93 compared to $8.26 a year ago, an increase of 20%, driven by strong operational growth, led by the North American Pharmaceutical and Oncology & Multispecialty segments, and a lower share count.”
From its results filing (SEC filing · Aug 5)
Sales grew 11% a year over 5 years, fiscal 2021 to 2026.
Pays $3.76 a share a year.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | +4.0% | -0.7% | +0.2% |
| May 7, 2026 | -2.0% | -2.5% | -1.0% |
| Feb 4, 2026 | +4.9% | +16.5% | +16.0% |
Sales grew every year from 2019 to 2026, to $403B. It made a profit in seven of the eight years.
One insider sold $269K across 1 filing in the last 6 months. No open-market buys on record. The newest:
18 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MCK is 0.8% of JEPI, 0.7% of SPMO, and 0.5% of VIG, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
MCK scores 15 today, which Breakaway calls Excellent. It is #1 of 5 in Wholesale-Drugs, Proprietaries & Druggists' Sundries by Quality Score, with 6 of 14 chart checks firing. Up 391% over five years while the S&P 500 rose 76%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MCK scores 15 today, which Breakaway calls Excellent (15 to 19). That is #1 of 5 in Wholesale-Drugs, Proprietaries & Druggists' Sundries by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MCK's 15.
One insider sold $269K across 1 filing in the last 6 months. No open-market buys on record. The newest is Bradley E. Lerman, Director, who sold $269K on Aug 10.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.